10.755 USD
+0.04 (+0.42%)
We assign a fundamental rating of 6 out of 10 to DVAX. DVAX was compared to 534 industry peers in the Biotechnology industry. DVAX has an average financial health and profitability rating. DVAX is not priced too expensively while it is growing strongly. Keep and eye on this one! These ratings could make DVAX a good candidate for growth investing.
1. Profitability
1.1 Basic Checks
DVAX had positive earnings in the past year.
In the past year DVAX had a positive cash flow from operations.
In multiple years DVAX reported negative net income over the last 5 years.
DVAX had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
With an excellent Return On Assets value of -4.59%, DVAX belongs to the best of the industry, outperforming 87.27% of the companies in the same industry.
DVAX has a Return On Equity of -8.13%. This is amongst the best in the industry. DVAX outperforms 89.14% of its industry peers.
DVAX has a Return On Invested Capital of 1.05%. This is amongst the best in the industry. DVAX outperforms 89.33% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.59% | ||
| ROE | -8.13% | ||
| ROIC | 1.05% |
ROA(3y)10.61%
ROA(5y)3.5%
ROE(3y)17.99%
ROE(5y)-8.35%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
In the last couple of years the Profit Margin of DVAX has declined.
DVAX's Operating Margin of 3.16% is amongst the best of the industry. DVAX outperforms 89.70% of its industry peers.
With an excellent Gross Margin value of 83.17%, DVAX belongs to the best of the industry, outperforming 85.77% of the companies in the same industry.
DVAX's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 3.16% | ||
| PM (TTM) | N/A | ||
| GM | 83.17% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-15.64%
PM growth 5YN/A
GM growth 3Y10.73%
GM growth 5Y12.85%
2. Health
2.1 Basic Checks
DVAX has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, DVAX has less shares outstanding
DVAX has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, DVAX has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of 1.70, we must say that DVAX is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of DVAX (1.70) is better than 66.29% of its industry peers.
DVAX has a debt to FCF ratio of 3.24. This is a good value and a sign of high solvency as DVAX would need 3.24 years to pay back of all of its debts.
With an excellent Debt to FCF ratio value of 3.24, DVAX belongs to the best of the industry, outperforming 92.70% of the companies in the same industry.
DVAX has a Debt/Equity ratio of 0.49. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.49, DVAX is doing worse than 71.72% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.49 | ||
| Debt/FCF | 3.24 | ||
| Altman-Z | 1.7 |
ROIC/WACC0.13
WACC8.13%
2.3 Liquidity
DVAX has a Current Ratio of 7.62. This indicates that DVAX is financially healthy and has no problem in meeting its short term obligations.
DVAX's Current ratio of 7.62 is fine compared to the rest of the industry. DVAX outperforms 73.22% of its industry peers.
DVAX has a Quick Ratio of 6.94. This indicates that DVAX is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 6.94, DVAX is doing good in the industry, outperforming 70.41% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.62 | ||
| Quick Ratio | 6.94 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 211.54% over the past year.
Measured over the past years, DVAX shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -19.10% on average per year.
The Revenue has grown by 26.73% in the past year. This is a very strong growth!
Measured over the past years, DVAX shows a very strong growth in Revenue. The Revenue has been growing by 51.10% on average per year.
EPS 1Y (TTM)211.54%
EPS 3Y-19.1%
EPS 5YN/A
EPS Q2Q%75%
Revenue 1Y (TTM)26.73%
Revenue growth 3Y-14.23%
Revenue growth 5Y51.1%
Sales Q2Q%17.67%
3.2 Future
The Earnings Per Share is expected to grow by 58.55% on average over the next years. This is a very strong growth
Based on estimates for the next years, DVAX will show a quite strong growth in Revenue. The Revenue will grow by 15.42% on average per year.
EPS Next Y-347.92%
EPS Next 2Y65.78%
EPS Next 3Y58.55%
EPS Next 5YN/A
Revenue Next Year20.52%
Revenue Next 2Y18.53%
Revenue Next 3Y17.48%
Revenue Next 5Y15.42%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 26.23, the valuation of DVAX can be described as expensive.
DVAX's Price/Earnings ratio is rather cheap when compared to the industry. DVAX is cheaper than 92.70% of the companies in the same industry.
DVAX's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 26.11.
The Price/Forward Earnings ratio is 21.74, which indicates a rather expensive current valuation of DVAX.
Based on the Price/Forward Earnings ratio, DVAX is valued cheaper than 92.88% of the companies in the same industry.
DVAX is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 36.21, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 26.23 | ||
| Fwd PE | 21.74 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, DVAX is valued cheaply inside the industry as 92.88% of the companies are valued more expensively.
DVAX's Price/Free Cash Flow ratio is rather cheap when compared to the industry. DVAX is cheaper than 95.88% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 15.68 | ||
| EV/EBITDA | 26.83 |
4.3 Compensation for Growth
DVAX has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as DVAX's earnings are expected to grow with 58.55% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y65.78%
EPS Next 3Y58.55%
5. Dividend
5.1 Amount
DVAX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:DVAX (12/2/2025, 1:29:54 PM)
10.755
+0.04 (+0.42%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners98.07%
Inst Owner Change-1.38%
Ins Owners0.56%
Ins Owner Change-11.93%
Market Cap1.26B
Revenue(TTM)330.51M
Net Income(TTM)-43.40M
Analysts80
Price Target23.46 (118.13%)
Short Float %11.76%
Short Ratio8.77
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)47.4%
Min EPS beat(2)30.1%
Max EPS beat(2)64.71%
EPS beat(4)3
Avg EPS beat(4)6.21%
Min EPS beat(4)-86.66%
Max EPS beat(4)64.71%
EPS beat(8)6
Avg EPS beat(8)-6.9%
EPS beat(12)9
Avg EPS beat(12)66.09%
EPS beat(16)11
Avg EPS beat(16)67.73%
Revenue beat(2)1
Avg Revenue beat(2)3.46%
Min Revenue beat(2)-1.05%
Max Revenue beat(2)7.97%
Revenue beat(4)1
Avg Revenue beat(4)-0.31%
Min Revenue beat(4)-4.19%
Max Revenue beat(4)7.97%
Revenue beat(8)2
Avg Revenue beat(8)-2.29%
Revenue beat(12)6
Avg Revenue beat(12)3.06%
Revenue beat(16)8
Avg Revenue beat(16)4.4%
PT rev (1m)-4.17%
PT rev (3m)-4.17%
EPS NQ rev (1m)-77.5%
EPS NQ rev (3m)-77.5%
EPS NY rev (1m)0%
EPS NY rev (3m)-4.79%
Revenue NQ rev (1m)3.77%
Revenue NQ rev (3m)3.77%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 26.23 | ||
| Fwd PE | 21.74 | ||
| P/S | 3.82 | ||
| P/FCF | 15.68 | ||
| P/OCF | 13.93 | ||
| P/B | 2.36 | ||
| P/tB | 2.37 | ||
| EV/EBITDA | 26.83 |
EPS(TTM)0.41
EY3.81%
EPS(NY)0.49
Fwd EY4.6%
FCF(TTM)0.69
FCFY6.38%
OCF(TTM)0.77
OCFY7.18%
SpS2.81
BVpS4.55
TBVpS4.53
PEG (NY)N/A
PEG (5Y)N/A
Graham Number6.48
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.59% | ||
| ROE | -8.13% | ||
| ROCE | 1.24% | ||
| ROIC | 1.05% | ||
| ROICexc | 3.98% | ||
| ROICexgc | 4.02% | ||
| OM | 3.16% | ||
| PM (TTM) | N/A | ||
| GM | 83.17% | ||
| FCFM | 24.37% |
ROA(3y)10.61%
ROA(5y)3.5%
ROE(3y)17.99%
ROE(5y)-8.35%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-15.64%
PM growth 5YN/A
GM growth 3Y10.73%
GM growth 5Y12.85%
F-Score5
Asset Turnover0.35
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.49 | ||
| Debt/FCF | 3.24 | ||
| Debt/EBITDA | 20.41 | ||
| Cap/Depr | 429.21% | ||
| Cap/Sales | 3.05% | ||
| Interest Coverage | 2.16 | ||
| Cash Conversion | 708.62% | ||
| Profit Quality | N/A | ||
| Current Ratio | 7.62 | ||
| Quick Ratio | 6.94 | ||
| Altman-Z | 1.7 |
F-Score5
WACC8.13%
ROIC/WACC0.13
Cap/Depr(3y)139.55%
Cap/Depr(5y)160.56%
Cap/Sales(3y)1.68%
Cap/Sales(5y)6.2%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)211.54%
EPS 3Y-19.1%
EPS 5YN/A
EPS Q2Q%75%
EPS Next Y-347.92%
EPS Next 2Y65.78%
EPS Next 3Y58.55%
EPS Next 5YN/A
Revenue 1Y (TTM)26.73%
Revenue growth 3Y-14.23%
Revenue growth 5Y51.1%
Sales Q2Q%17.67%
Revenue Next Year20.52%
Revenue Next 2Y18.53%
Revenue Next 3Y17.48%
Revenue Next 5Y15.42%
EBIT growth 1Y240.24%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year185.54%
EBIT Next 3Y81.5%
EBIT Next 5YN/A
FCF growth 1Y-31.63%
FCF growth 3Y-43.07%
FCF growth 5YN/A
OCF growth 1Y-25.53%
OCF growth 3Y-41.69%
OCF growth 5YN/A
DYNAVAX TECHNOLOGIES CORP / DVAX FAQ
What is the fundamental rating for DVAX stock?
ChartMill assigns a fundamental rating of 6 / 10 to DVAX.
What is the valuation status for DVAX stock?
ChartMill assigns a valuation rating of 6 / 10 to DYNAVAX TECHNOLOGIES CORP (DVAX). This can be considered as Fairly Valued.
Can you provide the profitability details for DYNAVAX TECHNOLOGIES CORP?
DYNAVAX TECHNOLOGIES CORP (DVAX) has a profitability rating of 6 / 10.
What is the expected EPS growth for DYNAVAX TECHNOLOGIES CORP (DVAX) stock?
The Earnings per Share (EPS) of DYNAVAX TECHNOLOGIES CORP (DVAX) is expected to decline by -347.92% in the next year.